Ann: Appendix 4C - Quarterly - 30 June 2023, page-21

clare1. "no mention of DX-3"!!!!!! Yes, WHY??
March QR. ."Patrys’ development program for PAT-DX3 remains on track with two major milestones achieved
during the March quarter. First, the Master Cell Bank (MCB) for the production of PAT-DX3 has been
completed and is currently undergoing stability testing. Second, Patrys’ CDMO successfully completed
a small-scale integration run for the production of PAT-DX3. An integration run is a scaled-down
version of an engineering run that combines the two major aspects of manufacturing; production (the
growing of cells in culture to produce antibody material); and purification (isolation of the antibody
from the production run).
Once the stability of the MCB is confirmed, Patrys will be able to initiate an engineering run of PAT-DX3
to produce larger amounts of antibody that can be used in the GLP toxicology studies to required
support the initiation of possible clinical trials for potential partnership opportunities.
Furthermore, we were delighted to report positive preclinical data on the ability of PAT-DX3 to be used for
synthetic lethality strategies which, along with its potential for the delivery of therapeutic payloads
into the cell and cell nucleus, remains an area of high interest with potential partners."

But, not one word since??????


~!